tl-895
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2020 (NCT04419623)
Timeline
Indications
Mechanism of action
- Stromal cell-derived factor 1INHIBITOR
CXCL12 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05280509 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2022 | Telios Pharma, Inc. |
| NCT04878003 | Phase 2 | Apr 13, 2021 | Kartos Therapeutics, Inc. |
| NCT04669067 | Phase 1/Phase 2 (Phase 2) | Feb 28, 2021 | Kartos Therapeutics, Inc., Telios Pharma, Inc. |
| NCT04640532 | Phase 1/Phase 2 (Phase 2) | Nov 17, 2020 | Kartos Therapeutics, Inc., Telios Pharma, Inc. |
| NCT04655118 | Phase 2 | Oct 22, 2020 | Telios Pharma, Inc. |
| NCT04419623 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2020 | Telios Pharma, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Telios Pharma, Inc. | For profit | 5 | 4 | 1 | 2020 |
| Kartos Therapeutics, Inc. | For profit | 3 | 2 | 1 | 2020 |
2 organizations
Page 1 / 1